Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RESTASIS vs RESTASIS MULTIDOSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin phosphatase inhibitor; inhibits T-cell activation and inflammatory cytokine production by blocking dephosphorylation of nuclear factor of activated T-cells (NFAT).
Cyclosporine A is a calcineurin inhibitor immunosuppressant. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T-cells). This reduces transcription of pro-inflammatory cytokines (e.g., IL-2) and T-cell activation, decreasing ocular surface inflammation.
FDA-approved: Increased tear production in patients with keratoconjunctivitis sicca (dry eye disease) due to ocular inflammation suppressed by prior anti-inflammatory treatment.,Off-label: Vernal keratoconjunctivitis, atopic keratoconjunctivitis, graft-versus-host disease-related dry eye, prevention of corneal graft rejection.
FDA: Increase tear production in patients with keratoconjunctivitis sicca (dry eye disease) due to ocular inflammation.,Off-label: Treatment of vernal keratoconjunctivitis, atopic keratoconjunctivitis, and prevention of corneal graft rejection.
One drop of 0.05% ophthalmic emulsion in each eye twice daily (approximately 12 hours apart).
One drop in each eye twice daily, approximately 12 hours apart. Administered as an ophthalmic emulsion.
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in clinical use for chronic dry eye disease.
Terminal half-life approximately 24 hours (range 18–36 h) following ocular administration, reflecting slow elimination from ocular tissues and systemic circulation.
Primarily hepatic via CYP3A4. Major metabolites are inactive. Elimination half-life: ~8.6 hours (systemic).
Primarily hepatic via CYP3A4 isoenzyme; cyclosporine is extensively metabolized with minimal renal excretion of parent drug.
Primarily fecal elimination (approximately 94% of the dose), with less than 1% excreted unchanged in urine. Renal elimination is a minor pathway.
Primarily biliary/fecal: ~85% of absorbed dose excreted in feces. Renal excretion minimal (<5%) as unchanged drug or metabolites.
Approximately 98% bound to plasma proteins, primarily albumin and lipoproteins.
Approximately 90% bound to plasma proteins (primarily albumin and lipoproteins).
Volume of distribution is approximately 2.5 L/kg, indicating extensive tissue distribution beyond total body water.
Volume of distribution not well defined after ocular use; systemically, Vd is low (<2 L/kg) indicating limited tissue distribution due to high protein binding.
After topical ophthalmic administration, systemic bioavailability is less than 0.1% (essentially negligible) due to low corneal permeability and rapid local clearance.
Ocular: systemic bioavailability <0.5% of instilled dose; negligible due to low corneal penetration and rapid clearance.
No clinically significant renal excretion; dose adjustment not required for renal impairment.
No dose adjustment required for renal impairment. Drug undergoes minimal systemic absorption.
No hepatic metabolism; dose adjustment not required for hepatic impairment.
No dose adjustment required for hepatic impairment. Not metabolized hepatically to a significant extent.
Safety and efficacy in pediatric patients below 16 years have not been established.
Safety and efficacy not established in pediatric patients; off-label use may consider adult dosing if indicated, but supported data are limited.
No specific dose adjustment; use same as younger adults. Caution with concomitant dry eye therapies.
Elderly patients may use the same dosing as adults; no specific geriatric dose adjustment is required.
None.
None. Restasis Multidose does not carry a black box warning; however, cyclosporine systemic formulations have warnings for increased risk of infection, lymphomas, and hypertension.
May cause nephrotoxicity and hypertension if significant systemic absorption occurs (rare with ophthalmic use). Ocular infections (e.g., herpes simplex) should be treated prior to therapy. Avoid with concurrent ocular surgery. May cause hypersensitivity reactions including anaphylaxis (rare). Monitor for development of lymphoproliferative disorders and skin malignancies (theoretical risk with systemic absorption).
Ocular infections should be resolved before initiating therapy.,May cause ocular burning, stinging, or discomfort; transient blurred vision.,Use with caution in patients with active herpes keratitis or other infections.,Long-term safety in patients with history of ocular herpes is not established.,Contains microemulsion vehicle; contact lens wearers should remove lenses prior to application and wait 15 minutes before reinsertion.
Absolute: Known hypersensitivity to cyclosporine or any component of the formulation. Relative: Active ocular infection; concurrent use with live vaccines (avoid); patients with a history of seizures (caution due to potential neurotoxicity).
Hypersensitivity to cyclosporine or any component of the formulation.,Active ocular infections (bacterial, viral, fungal).
No specific food interactions documented for ophthalmic cyclosporine. Systemic absorption is minimal.
No known food interactions with topical ophthalmic cyclosporine. Grapefruit juice may increase systemic levels, but systemic absorption is minimal with eye drops.
Category C. No adequate studies in pregnant women. In animal studies, cyclosporine (active ingredient) was embryotoxic and fetotoxic at doses toxic to dams. No evidence of teratogenicity in rats or rabbits. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
FDA Pregnancy Category C. In animal studies, cyclosporine (0.2-2 times the human topical ocular dose) caused embryotoxic and fetotoxic effects (increased pre- and postnatal mortality, reduced fetal weight) at maternal toxic doses. No adequate studies in pregnant women. Risk cannot be ruled out in first, second, or third trimester; use only if potential benefit justifies potential risk to fetus.
Cyclosporine is excreted in human milk. M/P ratio not reported for ophthalmic use. Due to potential for serious adverse reactions in nursing infants, caution should be exercised. Decision to discontinue nursing or drug should consider importance of drug to mother.
Cyclosporine is excreted in human milk after systemic administration. However, topical ocular administration results in negligible systemic absorption (blood concentrations below 100 ng/m L). M/P ratio not established. Caution is advised; consider developmental and health benefits of breastfeeding along with mother's clinical need for Restasis.
No dosage adjustment required for ophthalmic use. Systemic absorption is minimal; pharmacokinetic changes in pregnancy are unlikely to affect topical dosing.
No dose adjustment required for Restasis Multidose (cyclosporine ophthalmic emulsion 0.05%) during pregnancy. Systemic absorption is minimal (mean blood concentration < 0.1 ng/m L) and not expected to change with pregnancy-related pharmacokinetic alterations.
Restasis (cyclosporine ophthalmic emulsion) 0.05% is an immunomodulator used for dry eye disease. It requires at least 3-6 months for maximal effect; do not expect immediate relief. Warn patients about transient stinging or burning upon instillation. Contact lenses should be removed before application and may be reinserted after 15 minutes. Restasis does not contain preservatives; each single-use vial should be discarded immediately after use. It is pregnancy category C.
Restasis Multidose contains cyclosporine 0.05% ophthalmic emulsion. Shake well before each use. Tear function may improve after 3-6 months of continuous use. Do not administer while wearing contact lenses; remove lenses before instillation and wait 15 minutes before reinserting. May cause temporary blurred vision. If used with other ophthalmic drops, separate by at least 15 minutes.
Restasis may take up to 6 months to show full benefit for dry eye symptoms.,Apply one drop in each eye twice daily, about 12 hours apart.,Remove contact lenses before using and wait 15 minutes before reinserting.,Do not touch the tip of the vial to your eye or any surface.,Use each single-use vial immediately after opening; discard any unused portion.,You may experience temporary burning or stinging upon application.
Shake the bottle vigorously for 15 seconds before each use.,Remove contact lenses before applying and wait 15 minutes before reinserting.,Tilt head back, pull down lower eyelid, and instill one drop in each eye twice daily, about 12 hours apart.,Do not touch the tip of the bottle to your eye or any surface to avoid contamination.,Temporary blurring or stinging may occur; do not perform other tasks until vision clears.,Store upright at room temperature, 15-25°C (59-77°F). Do not freeze.,Do not use if the emulsion looks separated or if the bottle is damaged.,Report any signs of eye infection, pain, redness, or vision changes to your doctor.,It may take several weeks to months to feel the full benefit; consistent use is important.,Avoid sharing the bottle with others.
No interactions on record
No interactions on record
Common clinical questions about RESTASIS vs RESTASIS MULTIDOSE, answered by our medical review team.
RESTASIS is a Calcineurin Inhibitor Ophthalmic that works by Calcineurin phosphatase inhibitor; inhibits T-cell activation and inflammatory cytokine production by blocking dephosphorylation of nuclear factor of activated T-cells (NFAT).. RESTASIS MULTIDOSE is a Calcineurin Inhibitor Ophthalmic that works by Cyclosporine A is a calcineurin inhibitor immunosuppressant. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T-cells). This reduces transcription of pro-inflammatory cytokines (e.g., IL-2) and T-cell activation, decreasing ocular surface inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RESTASIS and RESTASIS MULTIDOSE depend on the specific clinical indication. These are both Calcineurin Inhibitor Ophthalmic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RESTASIS is: One drop of 0.05% ophthalmic emulsion in each eye twice daily (approximately 12 hours apart).. The standard adult dose of RESTASIS MULTIDOSE is: One drop in each eye twice daily, approximately 12 hours apart. Administered as an ophthalmic emulsion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RESTASIS and RESTASIS MULTIDOSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RESTASIS is classified as Category C. Category C. No adequate studies in pregnant women. In animal studies, cyclosporine (active ingredient) was embryotoxic and fetotoxic at doses toxic to dams. No evidence of teratoge. RESTASIS MULTIDOSE is classified as Category C. FDA Pregnancy Category C. In animal studies, cyclosporine (0.2-2 times the human topical ocular dose) caused embryotoxic and fetotoxic effects (increased pre- and postnatal mortali. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.